Frazier Life Sciences Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Frazier Life Sciences Management reported a $4.6 bn portfolio of 40 companies (41 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are MIRM, NAMS, ERAS. During the quarter it opened Achieve Life Sciences and Design Therapeutics and exited Revolution Medicines and Agios Pharmaceuticals.
Sections with a free account
What changed this quarter
15 positions with a change (4 new, 8 added to, 1 trimmed, 2 sold); also, 1 entered through an IPO, 1 exited through an acquisition or merger, 1 entered through a spin-off. 9 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedParabilis MedicinesPBLS1.1% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- BridgeBio Pharma−55%fewer sharesReduced6.6% → 2.5%
- Revolution Medicines−1.4 ppof portfolioSold out1.7% → —
- Achieve Life Sciences+1.1 ppof portfolioNew— → 1.1%
- Agios Pharmaceuticals−0.9 ppof portfolioSold out1.1% → —
- NewAmsterdam Pharma+6.8%more sharesIncreased14.0% → 13.3%
- Allogene Therapeutics+491%more sharesIncreased0.2% → 1.0%
- Design Therapeutics+0.6 ppof portfolioNew— → 0.6%
- Shattuck Labs+0.6 ppof portfolioNew— → 0.6%
- Ascendis Pharma A/s+69%more sharesIncreased0.8% → 1.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Mirum PharmaceuticalsMIRM19.6%
- NewAmsterdam PharmaNAMS · NAMSW13.6%
- ErascaERAS10.0%
- MBX BiosciencesMBX8.0%
- Arcutis BiotherapeuticsARQT5.6%
- Trevi TherapeuticsTRVI4.0%
- Krystal BiotechKRYS3.9%
- MAZE TherapeuticsMAZE3.3%
- Phathom PharmaceuticalsPHAT2.9%
- Palvella TherapeuticsPVLA2.9%
- BridgeBio PharmaBBIO2.5%
- Disc MedicineIRON2.2%
- CytokineticsCYTK2.2%
- Dyne TherapeuticsDYN1.5%
- Ascendis Pharma A/s1.3%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● No sector 1%
How its portfolio changed (8 quarters)
Q2 2026: 41
Q2 2026: 74%
Q2 2026: 6.1%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Brave Warrior AdvisorsInvestment firm · $4.6 bn
- Comgest Global Investors S.a.sInvestment firm · $4.5 bn
- Third PointInvestment firm · $4.6 bn
- Starboard ValueInvestment firm · $4.5 bn
- Fundsmith Investment ServicesInvestment firm · $4.5 bn
- Alphinity Investment Management PtyInvestment firm · $4.5 bn